Open AccessKRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab
Author(s) -
Hideaki Bando,
Takayuki Yoshino,
Katsuya Tsuchihara,
Naomi Ogasawara,
Nozomu Fuse,
Takashi Kojima,
Makoto Tahara,
Motohiro Kojima,
Kensuke Kaneko,
Toshihiko Doi,
Atsushi Ochiai,
Hiroyasu Esumi,
Atsushi Ohtsu
Publication year - 2011
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/bjc.2011.247
Subject(s) - kras , cetuximab , medicine , refractory (planetary science) , oncology , gastroenterology , biology , colorectal cancer , cancer , astrobiology
We aimed to compare the sensitive and quality-controlled KRAS testing with direct sequencing and to assess the impact on decision making of treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom